Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease.
Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello CA, Baldissera E, Dagna L. Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019 02 13; 21(1):54.